XCUR
What one share of Exicure holds
Pharmaceutical Preparations
Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value.
Exicure’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.30 |
| Capex (buildings and equipment) | −$0.05 |
| Free cash flow | −$1.00 |
| Cash and investments | $0.27 |
| Book value | $0.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$163.21 | $13.73 | −$307.05 | — | — |
| 2018 | — | −$81.62 | $0.34 | −$71.31 | — | $70.85 |
| 2019 | — | −$68.41 | $2.81 | $0.61 | — | $140.72 |
| 2020 | — | −$42.43 | $5.45 | −$73.00 | — | $105.26 |
| 2021 | — | −$108.50 | $1.64 | −$60.58 | — | $15.49 |
| 2022 | — | −$2.79 | $0.01 | −$38.61 | — | $15.02 |
| 2023 | — | −$10.55 | $0.00 | −$6.46 | — | $1.65 |
| 2024 | $0.24 | −$4.75 | $0.00 | −$1.42 | — | — |
| 2025 | $0.00 | −$0.79 | $0.00 | −$1.36 | — | $0.62 |